- Home
- RERE vs TBPH Comparison
RERE vs TBPH Comparison
Compare RERE & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | TBPH |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 908.9M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RERE | TBPH |
|---|---|---|
| Price | $4.11 | $17.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | ★ 1.1M | 377.6K |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $25.70 | $8.46 |
| Revenue Next Year | $22.93 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.50 | $13.08 |
| 52 Week High | $6.47 | $21.03 |
Technical Indicators
Market Signals| Indicator | RERE | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 59.46 |
| Support Level | $3.96 | $16.80 |
| Resistance Level | $4.29 | $17.17 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 13.04 | 93.75 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platforms PJT Marketplace and Paipai Marketplace. The Company's principal operations and geographic markets are in the People's Republic of China.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.